Multivalent Porous Silicon Nanoparticles Enhance the Immune Activation Potency of Agonistic CD40 Antibody

被引:71
|
作者
Gu, Luo [1 ]
Ruff, Laura E. [2 ]
Qin, Zhengtao [1 ]
Corr, Maripat [3 ]
Hedrick, Stephen M. [4 ]
Sailor, Michael J. [1 ]
机构
[1] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
CROSS-PRESENTATION; DRUG-DELIVERY; QUANTUM DOTS; CELLS; MICROPARTICLES; IMMUNOTHERAPY; RESPONSES; INTERNALIZATION; DISSOLUTION; INDUCTION;
D O I
10.1002/adma.201200776
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
One of the fundamental paradigms in the use of nanoparticles to treat disease is to evade or suppress the immune system in order to minimize systemic side effects and deliver sufficient nanoparticle quantities to the intended tissues. However, the immune system is the body's most important and effective defense against diseases. It protects the host by identifying and eliminating foreign pathogens as well as self-malignancies. Here we report a nanoparticle engineered to work with the immune system, enhancing the intended activation of antigen presenting cells (APCs). We show that luminescent porous silicon nanoparticles (LPSiNPs), each containing multiple copies of an agonistic antibody (FGK45) to the APC receptor CD40, greatly enhance activation of B cells. The cellular response to the nanoparticle-based stimulators is equivalent to a 30-40 fold larger concentration of free FGK45. The intrinsic near-infrared photoluminescence of LPSiNPs is used to monitor degradation and track the nanoparticles inside APCs.
引用
收藏
页码:3981 / 3987
页数:7
相关论文
共 50 条
  • [31] CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy
    Byrne, Katelyn T.
    Leisenring, Nathan H.
    Bajor, David L.
    Vonderheide, Robert H.
    JOURNAL OF IMMUNOLOGY, 2016, 197 (01): : 179 - 187
  • [32] Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
    Morrison, Alexander H.
    Diamond, Mark S.
    Hay, Ceire A.
    Byrne, Katelyn T.
    Vonderheide, Robert H.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (14) : 8022 - 8031
  • [33] Activation of APCs by CD40 ligation does not abrogate the induction of immune tolerance by oral antigen
    Chung, Y
    Kim, DH
    Lee, SH
    Kang, CY
    FASEB JOURNAL, 2003, 17 (07): : C321 - C322
  • [34] The co-expression of TLR4 and CD40 homodimer enhance B cell activation
    Nadiri, Amal
    Jundi, Malek
    Yacoub, Daniel
    Mourad, Walid
    JOURNAL OF IMMUNOLOGY, 2013, 190
  • [35] Agonistic anti-CD40 antibody profoundly suppresses the immune response to infection with lymphocytic choriomeningitis virus
    Bartholdy, Christina
    Kauffmann, Susanne Ording
    Christensen, Jan Pravsgaard
    Thomsen, Allan Randrup
    JOURNAL OF IMMUNOLOGY, 2007, 178 (03): : 1662 - 1670
  • [36] Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma
    Bajor, David L.
    Mick, Rosemarie
    Riese, Matthew J.
    Richman, Lee P.
    Xu, Xiaowei
    Torigian, Drew A.
    Stelekati, Erietta
    Sweeney, Martha
    Sullivan, Brendan
    Schuchter, Lynn M.
    Amaravadi, Ravi
    Wherry, E. John
    Vonderheide, Robert H.
    CANCER RESEARCH, 2015, 75
  • [37] Nonredundant roles for immune checkpoint blockade and agonistic CD40 in mediating T-cell responses in pancreatic ductal adenocarcinoma
    Morrison, Alexander H.
    Byrne, Katelyn T.
    Vonderheide, Robert H.
    CANCER RESEARCH, 2018, 78 (13)
  • [38] Transfection of CD40 in a human oral squamous cell carcinoma keratinocyte line upregulates immune potency and costimulatory molecules
    Dorrego, MV
    Whawell, SA
    Speight, PM
    Barrett, AW
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (02) : 231 - 238
  • [39] CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy
    Juan Zhang
    Lei Wang
    Shuyi Li
    Xuefeng Gao
    Zhong Liu
    Cancer Cell International, 22
  • [40] CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy
    Zhang, Juan
    Wang, Lei
    Li, Shuyi
    Gao, Xuefeng
    Liu, Zhong
    CANCER CELL INTERNATIONAL, 2022, 22 (01)